ArticleCancer research communications2025
Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil Extracellular Traps in Pancreatic Ductal Adenocarcinoma: A Vicious Cycle in the Tumor Microenvironment and Targeted Interventions.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly chemoresistant malignancy with a dismal 11% 5-year survival rate. PDAC tumors are composed of a dense desmoplastic stroma, and the interaction of this collagen-rich tumor microenvironment with PDAC cells promotes their aggressive growth and metastatic spread. In this study, we investigated the role of collagen XVII, a unique transmembrane collagen that connects the extracellular matrix to cytoplasmic signaling complexes. Examination of PDAC tumors revealed that its expression is an independent prognostic biomarker associated with worsened oncological outcomes. Xenograft tumor studies and in vitro coculture experiments with PDAC cell lines and immortalized cancer-associated fibroblasts defined a critical role for the tumor microenvironment in mediating the expression of collagen XVII in the cancer compartment of PDAC tumors. Genetic depletion of collagen XVII reduces the viability and migration of PDAC cells in vitro and orthotopic tumor formation in vivo, underscoring its critical role in PDAC tumor biology. Tumors formed by collagen XVII-depleted PDAC cells exhibit a dramatic downregulation of phosphoinositide 3-kinase regulatory subunit 5, a regulatory subunit of the class I phosphatidylinositol 3-kinase (PI3K) γ complex, and decreased levels of downstream activated AKT. Taken together, these findings reveal collagen XVII signaling as a novel target for PDAC treatment and provide insight into the mechanisms by which it regulates PI3K activity. SIGNIFICANCE: Our study highlights the importance of cross-talk between the tumor microenvironment and PDAC cells in mediating the expression of a key signaling pathway responsible for PI3K activity in PDAC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.